Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-valent HPV Vaccine in Chinese Males
NCT06465914Phase 3Active, not recruiting
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in genital warts, penile cancer, anal cancer and 1 more comparing 9-valent HPV Vaccine with Placebo (2 arms). Primary endpoint: Incidence of vaccine HPV types-related genital warts. Started Jul 2024; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine (Hansenula polymorpha)
03
Conditions
genital wartspenile canceranal cancerHPV-related carcinoma
Beyond the preview
Go deeper on NCT06465914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465914.